Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05225428 · ClinicalTrials.gov registry record · NA

Video Education With Result Dependent dIsclosure

A NA study of Breast Cancer and Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
1,020
Enrollment target
1
Study location

NCT05225428 is a NA study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,020 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05225428, a NA study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
1,020 participants
Enrollment target
1
Study location

Study Summary

The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.

Interventions

  • BEHAVIORAL Video Education
  • BEHAVIORAL Genetic Counseling

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 1,020 participants
Start Date 2022-08-04
Est. Completion 2026-09-01
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT05225428

The ClinicalTrials.gov registry entry for NCT05225428 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,020 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Video Education is the first listed.

NCT05225428 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05225428 about?

NCT05225428 is a clinical study titled "Video Education With Result Dependent dIsclosure". The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better se...

What is the current status of trial NCT05225428?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,020 participants. The study started on 2022-08-04. Estimated completion is 2026-09-01.

What conditions does trial NCT05225428 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer.

What interventions are being tested in trial NCT05225428?

The interventions under investigation include: Video Education (BEHAVIORAL), Genetic Counseling (BEHAVIORAL).

Who is sponsoring clinical trial NCT05225428?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05225428 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.